Investing

CNBC’s Jim Cramer implored investors on Thursday not to let day-to-day market volatility frighten them out of buying shares of great long-term performers like pharmaceutical giant Merck. “Merck is exactly the kind of company that investors circle the wagons around” during difficult macroeconomic events like long-lived government shutdowns, Cramer said on “Mad Money” amid a
0 Comments
The current macroeconomic environment makes it difficult for CNBC’s Jim Cramer to recommend even a best-of-breed stock like Emerson Electric, he said Wednesday after a solid trading session in the stock market. An old-line manufacturer involved in the industrial automation, fluid handling, climate control and oil and gas spaces, Emerson has been at the center
0 Comments
Sometimes, no movement is good movement. In the case of the government shutdown, money manager Larry Glazer believes it’s favorable for Wall Street — at least in the short term. His reasoning: It prevents lawmakers from passing policies that could be detrimental to corporate America. “Investors like less Washington, and they realize Washington isn’t always
0 Comments
Wall Street’s recent distaste with the retail sector is evidence that the economic layout is changing for public retail companies, CNBC’s Jim Cramer said Thursday as the group slid on holiday sales disappointments. “Welcome to the new economy,” Cramer said. “Going forward, you need to understand that not all retailers are created equal anymore, and
0 Comments
Investors shouldn’t wait for “ironclad proof” that business is improving at Micron, Nvidia and Lam Research before they buy the semiconductor companies’ stocks, CNBC’s Jim Cramer said Wednesday as stocks inched higher. “If you wait for ironclad proof that a troubled business has turned itself around, you’ll miss most of the upside from that turn,”
0 Comments
Patient investors might want to consider buying shares of Micron Technology as things slowly turn positive for the chipmaker, CNBC’s Jim Cramer said Monday as Micron’s stock pulled the semicondcutor cohort higher. Shares of Micron mounted a long-awaited recovery in Monday’s turbulent trading session after BMO Capital Markets analysts upgraded the stock to “buy” from
0 Comments
If not for the plunge in Apple’s stock on Thursday, Wall Street would’ve been laser-focused on the monumental tie-up between biotechnology giants Bristol-Myers Squibb and Celgene, CNBC’s Jim Cramer said. “If not for the Apple shortfall today — worst in 6 years, by the way — this Bristol-Myers-Celgene deal would’ve been all we talked about,”
0 Comments
Investors should be careful as the recent spike in market volatility is far from normal, according to the manager of the California State Teachers’ Retirement System, which has more than $200 billion in assets. “The last few days have been abnormal volatility,” Christopher Ailman, chief investment officer at CalSTRS, told CNBC during a special aired
0 Comments